Moderna’s stock fell in early February, even though the Food and Drug Administration received a breakthrough approval for its experimental RSV vaccine.

Moderna (MRNA) said its vaccine in 37,000 people aged 60 and older was nearly 84 percent effective against the mild form of the disease and more than 82 percent effective against the severe form of RSV.

This puts Moderna right behind Pfizer (PFE) and GSK (GSK), which are soon to undergo Food and Drug Administration review of their RSV vaccines.

Moderna recently announced its $85 million acquisition of OriCiro Genomics. This private biotechnology company works in DNA synthesis and amplification. Moderna also signed a research agreement with CytomX Therapeutics (CTMX), which works in cancer treatment.